Back to results
US 11,529,365 B2Granted
Synthetic composition for microbiota modulation
AssigneeGlycom A/S
InventorsBruce McConnell, Louise Kristine Vigsnæs
Life of this patent
Estimating the term…
Abstract
A method and composition including an effective amount of one or more synthetic neutral HMOs are disclosed for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation and for improving one or more gastrointestinal conditions.
Claims15
A method comprising:
- selecting a non-infant human having an impaired gut barrier function and carrying an FUT2 mutation associated with an FUT2 non-secretor status;
- selecting an effective amount of one or more neutral human milk oligosaccharides (“HMOs”) selected from 2′-fucosyllactose (2′-FL), difucosyllactose (DFL), 3-fucosyllactose (3-FL), lacto-N-fucopentaose I (LNFP-I), lacto-N-neotetraose (LNnT), lacto-N-tetraose (LNT), and mixtures thereof, the selected amount effective to increase a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human;
- and
- increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human and improving the gut barrier function of the non-infant human by administering the effective amount of the selected HMOS to the non-infant human.
1 more element
A method comprising:
- selecting an obese non-infant human carrying an FUT2 mutation associated with an FUT2 non-secretor status;
- selecting an effective amount of one or more neutral human milk oligosaccharides (“HMOs”) selected from 2′-fucosyllactose FL), difucosyllactose (DFL), 3-fucosyllactose (3-FL), lacto-N-fucopentaose I (LNFP-I), lacto-N-neotetraose (LNnT), lacto-N-tetraose (LNT), and mixtures thereof, the selected amount effective to increase a relative abundance of Bifidobacterium adolescentis in the microbiota of the non-infant human
- increasing the relative abundance of Bifidobacterium adolescentis in the microbiota in the gastro-intestinal tract of the non-infant human carrying the FUT2 mutation and reducing one or more conditions associated with increased risk of obesity by administering the effective amount of the selected HMOs to the non-infant human.
A method comprising:
- selecting a non-infant irritable bowel symptom (IBS) patient carrying an FUT2 mutation associated with an FUT2 non-secretor status;
- selecting an effective amount of one or more synthetic neutral human milk oligosaccharides (“HMOs”) selected from 2′-fucosyllactose (2′-FL), difucosyllactose (DFL), 3-fucosyllactose (3-FL), lacto-N-fucopentaose I (LNFP-I), lacto-N-neotetraose (LNnT), lacto-N-tetraose (LNT), and mixtures thereof, the selected amount effective to increase the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human;
- and
- increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human and reducing one or more IBS symptoms by administering the effective amount of the selected HMOs to the non-infant human.
1 more element
Dependencies are inferred from the claim text.